EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lasting response by vertical inhibition with cetuximab and trametinib in KRAS ‐mutated colorectal cancer patient‐derived xenografts

Timm M Reissig iD, Swetlana Ladigan-Badura, Anja Steinberg, Abdelouahid Maghnouj, Ting Li, Berlinda Verdoodt, Sven T Liffers, Michael Pohl, Heiner Wolters, Christian Teschendorf, Richard Viebahn, Jakob Admard und 5 weitere

Molecular Oncology · 2023-11 · 17 (11) · 2396-2414

DOI: 10.1002/1878-0261.13510 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 03.09.2023. Verfasst von Timm M Reissig und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular GI Oncology, Faculty of Medicine, Ruhr-University Bochum, Germany. Hauptthemen laut MEDLINE: Antineoplastic Agents, Colorectal Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Krebshilfe, Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although approximately half of all metastatic colorectal cancers (mCRCs) harbour mutations in KRAS or NRAS , hardly any progress has been made regarding targeted treatment for this group over the last few years. Here, we investigated the efficacy of vertical inhibition of the RAS‐pathway by targeting epidermal growth factor receptor (EGFR) and mitogen‐activated protein kinase kinase (MEK) in patient‐derived xenograft (PDX) tumours with primary KRAS mutation. In total, 19 different PDX models comprising 127 tumours were tested. Responses were evaluated according to baseline tumour volume changes and graded as partial response (PR; ≤ − 30%), stable disease (SD; between −30% and +20%) or progressive disease (PD; ≥ + 20%). Vertical inhibition with trametinib and cetuximab induced SD or PR in 74% of analysed models, compared to 24% by monotherapy with trametinib. In cases of PR by vertical inhibition (47%), responses were lasting (as long as day 137), with a low incidence of secondary resistance (SR). Molecular analyses revealed that primary and SR was driven by transcriptional reprogramming activating the RAS pathway in a substantial fraction of tumours. Together, these preclinical data strongly support the translation of this combination therapy into clinical trials for CRC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsColorectal NeoplasmsHumansCetuximabProto-Oncogene Proteins p21(ras)HeterograftsMitogen-Activated Protein Kinase KinasesMutationPyridonesPyrimidinones

Stichwörter der Autor:innen

CRCEGFRMEKPDXresistancetargeted therapy

Substanzen

CetuximabAntineoplastic AgentsProto-Oncogene Proteins p21(ras)Mitogen-Activated Protein Kinase KinasestrametinibPyridonesPyrimidinonesKRAS protein, human

Autor:innen und Institutionen

  • Department of Molecular GI Oncology, Faculty of Medicine, Ruhr-University Bochum, Germany.
  • Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Germany.
  • Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Germany.
  • Center for Hemato-Oncological Diseases, University Hospital Knappschaftskrankenhaus, Ruhr-University Bochum, Germany.
  • Institute of Pathology, Ruhr University Bochum, Germany.
  • Department of Visceral and General Surgery, St. Josef Hospital, Dortmund, Germany.

ORCID-Profile: Timm M Reissig, Stephan A Hahn, Deepak B Vangala

Förderung

  • Deutsche Krebshilfe
  • Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen

Zitieren

APA

Reissig, T. M., Ladigan-Badura, S., Steinberg, A., Maghnouj, A., Li, T., Verdoodt, B., Liffers, S. T., Pohl, M., Wolters, H., Teschendorf, C., Viebahn, R., Admard, J., Casadei, N., Tannapfel, A., Schmiegel, W., Hahn, S. A., & Vangala, D. B. (2023). Lasting response by vertical inhibition with cetuximab and trametinib in KRAS ‐mutated colorectal cancer patient‐derived xenografts. Molecular Oncology, 17(11), 2396-2414. https://doi.org/10.1002/1878-0261.13510

Vancouver

Reissig TM, Ladigan-Badura S, Steinberg A, Maghnouj A, Li T, Verdoodt B, et al. Lasting response by vertical inhibition with cetuximab and trametinib in KRAS ‐mutated colorectal cancer patient‐derived xenografts. Molecular Oncology. 2023;17(11):2396-2414. doi:10.1002/1878-0261.13510

BibTeX
@article{Reissig2023,
  author = {Reissig, Timm M and Ladigan-Badura, Swetlana and Steinberg, Anja and Maghnouj, Abdelouahid and Li, Ting and Verdoodt, Berlinda and Liffers, Sven T and Pohl, Michael and Wolters, Heiner and Teschendorf, Christian and Viebahn, Richard and Admard, Jakob and Casadei, Nicolas and Tannapfel, Andrea and Schmiegel, Wolff and Hahn, Stephan A and Vangala, Deepak B},
  title = {Lasting response by vertical inhibition with cetuximab and trametinib in KRAS ‐mutated colorectal cancer patient‐derived xenografts},
  journal = {Molecular Oncology},
  year = {2023},
  volume = {17},
  number = {11},
  pages = {2396--2414},
  doi = {10.1002/1878-0261.13510}
}
Kostenlos starten →